Cravath, Swaine & Moore LLP Logo
  • Practices
  • People
  • Careers
  • News & Insights
  • Practices
  • People
  • Careers
  • News & Insights
  • Our Story
  • The Cravath System
  • Diversity & Inclusion
  • Pro Bono
  • Alumni Journal
  • 200.Cravath

Cravath’s London Office Moves to 100 Cheapside

Read More

News & Insights

Andrew Davis Speaks at PLI’s Tax Strategies 2025 Program

December 12, 2025

On December 11, 2025, Cravath partner Andrew T. Davis participated in “Tax Strategies for Corporate Acquisitions, Dispositions, Spin‑Offs, Joint Ventures, Financings, Reorganizations & Restructurings 2025,” a program presented by the Practising Law Institute from December 10‑12 in Los Angeles. The program reviewed the tax issues presented by major corporate transactions, including single‑buyer acquisitions of a division or subsidiary, multi‑party joint ventures, cross‑border mergers and complex acquisitions of public companies with domestic and foreign operations. Andrew spoke on a panel entitled “Impact of the Corporate Alternative Minimum Tax (“CAMT”) on M&A Transactions,” which explored the CAMT rules and consequences for taxable and tax‑free acquisitions and dispositions, including spin‑offs, and reviewed the calculation of alternative minimum taxable income and other key issues addressed or unaddressed by IRS guidance.

Related Practices & Industries

  • Tax
  • Corporate
  • Mergers and Acquisitions

Speakers

Photo
Name
Andrew T. Davis
Title
Tax
Title
Partner
Email
adavis@cravath.com
Phone
+1-212-474-1272
vCard
Download vCard

    Education

    • LL.M., 2020, New York University School of Law
    • J.D., 2014, Stanford Law School
    • A.B., 2010, Princeton University

    Admitted In

    • New York

    Related News & Insights

    Deals & Cases

    December 09, 2025

    Paramount’s $108.4 Billion All-Cash Tender Offer to Acquire Warner Bros. Discovery, Inc.

    On December 8, 2025, Paramount, a Skydance Corporation (“Paramount”), announced it has commenced an all-cash tender offer to acquire all of the outstanding shares of Warner Bros. Discovery, Inc. (“WBD”) for $30.00 per share in cash, equating to an enterprise value of $108.4 billion. Paramount’s proposed transaction is for the entirety of WBD, including the Global Networks segment. Cravath is representing Paramount in connection with the transaction.

    Deals & Cases

    December 01, 2025

    Polaris Inc.’s Registered Senior Notes Offering

    Cravath represented the underwriters in connection with the $500 million registered senior notes offering of Polaris Inc. Polaris Inc. designs, engineers, manufactures and markets powersport vehicles and also designs and manufactures or sources parts, garments and accessories. The transaction closed on November 13, 2025.

    Deals & Cases

    November 26, 2025

    Robinhood’s Joint Venture and Partnership with Susquehanna to Operate CFTC-Licensed Exchange and Clearinghouse

    On November 25, 2025, Robinhood Markets, Inc. (“Robinhood”) announced it is extending its prediction markets offering through a new joint venture and partnership with Susquehanna International Group (“Susquehanna”) to operate a CFTC-licensed exchange and clearinghouse. Robinhood will serve as the controlling partner. The independent joint venture will serve Futures Commission Merchant platforms with futures and derivative products, including prediction markets. The venture will accelerate delivery of its services by acquiring MIAXdx, a CFTC-licensed Designated Contract Market, Derivatives Clearing Organization and Swap Execution Facility, and wholly-owned subsidiary of Miami International Holdings, Inc. (“MIAX”). MIAX will remain invested through a strategic 10% equity stake in the exchange. Cravath is representing Robinhood in connection with the transaction.

    Deals & Cases

    November 17, 2025

    Johnson & Johnson’s $3.05 Billion Acquisition of Halda Therapeutics OpCo, Inc.

    On November 17, 2025, Johnson & Johnson announced it has entered into a definitive agreement to acquire Halda Therapeutics OpCo, Inc., a clinical‑stage biotechnology company with a proprietary Regulated Induced Proximity TArgeting Chimera (RIPTACTM) platform to develop oral, targeted therapies for multiple types of solid tumors, including prostate cancer, for $3.05 billion in cash. Cravath is representing Johnson & Johnson in connection with the transaction.

    Cravath Bicentennial

    Celebrating 200 years of partnership. In 2019, we celebrated our bicentennial. Our history mirrors that of our nation. Integral to our story is our culture.

    Explore

    Cravath, Swaine & Moore LLP Logo
    • CONTACT US
    • OUR STORY
    • ALUMNI PORTAL
    • DISCLAIMERS & NOTICES

    Attorney Advertising. ©2025 Cravath, Swaine & Moore LLP.